Answers are grounded in this paper and cite their sources.
The promise of prostate-specific membrane antigen (PSMA)–targeted radionuclide therapy is being demonstrated by a growing number of reports detailing institutional experience with various agents, and prospective clinical trials are in progress to further establish the safety and efficacy of this
No takes yet. Share an insight, caveat, or question.
Taïeb et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: